Other anti-CD19-targeted DLBCL therapies include the antibody-drug conjugate loncastuximab tesirine, currently approved for r/r DLBCL patients after at least two previous lines of therapy, and the anti-CD19 chimeric antigen receptor T-cell (CART19) therapies axicabtagene-ciloleucel (axi-cel) and lisocabtagene maraleucel (liso-cel), approved as a second line of therapy and tisagenlecleucel (tisa-cel), as a third line of therapy (2–5). Here, CD19 is linked to diffuse large B-cell lymphoma.